1-7 of 7
Roy Herbst
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2541–2546.
https://doi.org/10.1158/1535-7163.MCT-12-0358
Published: 08 November 2012
View article titled, Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Open the PDF for Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist in another window
Journal Articles

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Emmanuelle J. Meuillet, Song Zuohe, Robert Lemos, Nathan Ihle, John Kingston, Ryan Watkins, Sylvestor A. Moses, Shuxing Zhang, Lei Du-Cuny, Roy Herbst, Jörg J. Jacoby, Li Li Zhou, Ali M. Ahad, Eugene A. Mash, D. Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (3): 706–717.
https://doi.org/10.1158/1535-7163.MCT-09-0985
Published: 09 March 2010
View article titled, Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Open the PDF for Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor in another window
Journal Articles

Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534)

David S. Hong, Darrin Davis, Aung Naing, Siqing Fu, Gerald Falchook, Linda W. Ricks, Nebe Bekele, David Mittleman, W. Liu, Percy Ivy, Roy Herbst, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A4.
https://doi.org/10.1158/1535-7163.TARG-09-A4
Published: 10 December 2009
View article titled, Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534)
Journal Articles

Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor

Garth Powis, Sylvestor A. Moses, Shuxing Zhang, Lei Du‐Cuny, Zuohe Song, Roy Herbst, Joerg Jacoby, Lynn Kirkpatrick, Eugene Mash, Emmanuelle J. Meuillet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B139.
https://doi.org/10.1158/1535-7163.TARG-09-B139
Published: 10 December 2009
View article titled, Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor
Journal Articles

Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of irinotecan in orthotopic human small cell lung cancer models

Roy Herbst, Kazuhisa Furutani, Ritsuko Komaki, Toshio Kuwai, Takeshi Isobe, Maria Korshunova, Baruch Erez, Anderson Ryan, Juliane Jurgensmeier, Michael O'Reilly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A26.
Published: 01 November 2007
View article titled, Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of irinotecan in orthotopic human small cell lung cancer models
Journal Articles

Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors

Emer Hanrahan, Ludmila Prudkin, Heather Yan Lin, Carmen Behrens, Erminia Massarelli, Matthew Herynk, Danny Du, Marie Wislez, Jonathan Kurie, Roy Herbst, J. Jack Lee, Ignacio Wistuba, John Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A24.
Published: 01 November 2007
View article titled, Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors
Journal Articles

Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of paclitaxel in orthotopic human lung adenocarcinoma models

Kazuhisa Furutani, Ritsuko Komaki, Toshio Kuwai, Joerg Jacoby, Maria Korshunova, Baruch Erez, Anderson Ryan, Juliane Jurgensmeier, Roy Herbst, Michael O'Reilly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A25.
Published: 01 November 2007
View article titled, Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of paclitaxel in orthotopic human lung adenocarcinoma models